Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
68,578,543
-
Total 13F shares
-
85,147,537
-
Share change
-
+3,643,862
-
Total reported value
-
$1,341,973,353
-
Put/Call ratio
-
3.4%
-
Price per share
-
$15.76
-
Number of holders
-
137
-
Value change
-
+$58,255,702
-
Number of buys
-
73
-
Number of sells
-
48
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) as of Q1 2024
As of 31 Mar 2024,
Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) was held by
137 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
85,147,537 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, EVENTIDE ASSET MANAGEMENT, LLC, FMR LLC, BlackRock Inc., VANGUARD GROUP INC, CITADEL ADVISORS LLC, STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, T. Rowe Price Investment Management, Inc., and Capital International Investors.
This page lists
138
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.